Free Trial

Bausch + Lomb (BLCO) Competitors

Bausch + Lomb logo
$13.51 +0.77 (+6.05%)
As of 01:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BLCO vs. SNN, SOLV, PEN, STVN, GKOS, NARI, INSP, SLNO, IRTC, and TMDX

Should you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Smith & Nephew (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), Soleno Therapeutics (SLNO), iRhythm Technologies (IRTC), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.

Bausch + Lomb vs.

Smith & Nephew (NYSE:SNN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.

Smith & Nephew presently has a consensus target price of $27.00, indicating a potential upside of 0.84%. Bausch + Lomb has a consensus target price of $18.82, indicating a potential upside of 40.49%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Smith & Nephew.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bausch + Lomb
1 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.25

Smith & Nephew has a net margin of 0.00% compared to Bausch + Lomb's net margin of -6.62%. Bausch + Lomb's return on equity of 3.35% beat Smith & Nephew's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & NephewN/A N/A N/A
Bausch + Lomb -6.62%3.35%1.66%

Smith & Nephew received 410 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 54.29% of users gave Smith & Nephew an outperform vote while only 41.49% of users gave Bausch + Lomb an outperform vote.

CompanyUnderperformOutperform
Smith & NephewOutperform Votes
449
54.29%
Underperform Votes
378
45.71%
Bausch + LombOutperform Votes
39
41.49%
Underperform Votes
55
58.51%

25.6% of Smith & Nephew shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 1.0% of Smith & Nephew shares are owned by company insiders. Comparatively, 0.2% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Smith & Nephew has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Smith & Nephew has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew$5.81B2.01$263M$2.1612.40
Bausch + Lomb$4.79B0.99-$317M-$0.91-14.72

In the previous week, Bausch + Lomb had 2 more articles in the media than Smith & Nephew. MarketBeat recorded 8 mentions for Bausch + Lomb and 6 mentions for Smith & Nephew. Smith & Nephew's average media sentiment score of 1.70 beat Bausch + Lomb's score of 0.17 indicating that Smith & Nephew is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Bausch + Lomb
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Smith & Nephew beats Bausch + Lomb on 12 of the 18 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLCO vs. The Competition

MetricBausch + LombOphthalmic goods IndustryMedical SectorNYSE Exchange
Market Cap$4.52B$10.88B$5.35B$18.67B
Dividend YieldN/A0.96%5.44%4.16%
P/E Ratio-14.0735.2921.9331.63
Price / Sales0.942.73396.6327.49
Price / Cash8.4114.5338.2017.53
Price / Book0.692.296.744.36
Net Income-$317M$224.27M$3.21B$1.02B
7 Day Performance6.07%2.81%5.31%1.58%
1 Month Performance-19.54%-16.31%-6.34%-7.33%
1 Year Performance-14.09%-24.89%16.32%1.81%

Bausch + Lomb Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLCO
Bausch + Lomb
3.9198 of 5 stars
$13.51
+6.1%
$18.82
+39.3%
-13.8%$4.77B$4.79B-14.8512,500Upcoming Earnings
Gap Up
SNN
Smith & Nephew
2.4922 of 5 stars
$25.71
-0.8%
$27.00
+5.0%
+7.0%$11.24B$5.81B11.9020,100
SOLV
Solventum
1.5821 of 5 stars
$64.08
-3.3%
$79.86
+24.6%
+3.9%$11.09B$8.25B23.3022,000
PEN
Penumbra
4.0681 of 5 stars
$270.53
-2.5%
$293.93
+8.7%
+35.2%$10.47B$1.19B795.683,900Earnings Report
Analyst Forecast
News Coverage
Gap Up
STVN
Stevanato Group
1.4106 of 5 stars
€21.65
-1.0%
N/A-19.7%$6.56B$1.10B46.064,650Analyst Upgrade
GKOS
Glaukos
4.6161 of 5 stars
$88.17
-2.3%
$156.17
+77.1%
-8.3%$4.99B$383.48M-30.72780Upcoming Earnings
NARI
Inari Medical
0.652 of 5 stars
$79.97
flat
$68.00
-15.0%
N/A$4.68B$493.63M-59.24800Upcoming Earnings
Positive News
INSP
Inspire Medical Systems
4.6729 of 5 stars
$144.74
-3.6%
$218.90
+51.2%
-36.6%$4.31B$802.80M83.67760Analyst Forecast
News Coverage
Positive News
SLNO
Soleno Therapeutics
4.8052 of 5 stars
$68.93
-1.5%
$99.63
+44.5%
+80.4%$3.16BN/A-20.7630Analyst Forecast
Positive News
IRTC
iRhythm Technologies
1.0467 of 5 stars
$98.63
-2.3%
$119.73
+21.4%
-11.8%$3.10B$591.84M-27.101,790Upcoming Earnings
TMDX
TransMedics Group
2.6679 of 5 stars
$87.72
-0.6%
$122.70
+39.9%
+1.9%$2.97B$441.54M93.32210Upcoming Earnings
Analyst Forecast

Related Companies and Tools


This page (NYSE:BLCO) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners